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OBJECTIVES We conducted a subgroup analysis in the Losartan Intervention For Endpoint reduction in
hypertension (LIFE) study to determine whether aspirin interacted with the properties of
losartan, an angiotensin-II receptor antagonist.
BACKGROUND Negative interactions between angiotensin-converting enzyme inhibitors and aspirin have
been reported. There are no data reported from clinical trials about possible interactions
between angiotensin-II receptor antagonists and aspirin.
METHODS The LIFE study assigned 9,193 patients with hypertension and left ventricular hypertrophy
(LVH) to losartan- or atenolol-based therapy for a mean of 4.7 years, with 1,970 (21.4%) taking
aspirin at baseline. The primary composite end point (CEP) included cardiovascular death, stroke,
and myocardial infarction (MI). The present cohort was stratified by aspirin use at baseline.
RESULTS Blood pressures were reduced similarly in the losartan with aspirin (n  1,004) and atenolol
with aspirin (n  966) groups. The CEP was reduced by 32% (95% confidence interval 0.55
to 0.86, p  0.001) with losartan with aspirin compared to atenolol with aspirin, adjusted for
Framingham risk score and LVH. The test for treatment versus aspirin interaction, excluding
other covariates, was significant for the CEP (p  0.016) and MI (p  0.037).
CONCLUSIONS There was a statistical interaction between treatment and aspirin in the LIFE study, with
significantly greater reductions for the CEP and MI with losartan in patients using aspirin
than in patients not using aspirin at baseline. Further studies are needed to clarify whether
this represents a pharmacologic interaction or a selection by aspirin use of patients more likely
to respond to losartan treatment. (J Am Coll Cardiol 2005;46:770–5) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.05.060American College of Cardiology Foundation
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The Losartan Intervention For Endpoint reduction in
ypertension (LIFE) study demonstrated that losartan-
ased therapy reduced cardiovascular end points signifi-
antly better than atenolol-based therapy for a similar
eduction in blood pressure (BP) in patients with hyperten-
ion and left ventricular hypertrophy (LVH) (1–5).
There are reports of negative interactions between aspirin
nd angiotensin-converting enzyme inhibitors in preventing
ardiovascular end points (6,7). These reports are not
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irmingham, Alabama; ##The Nordic School of Public Health, Göteborg, Sweden; aonsistent, and the interaction may be dose dependent
8–10). There are no data from large clinical trials regarding
otential interactions between AT1 antagonists and aspirin.
hus, we tested the hypothesis that aspirin does not interact
egatively with the beneficial properties of losartan.
ETHODS
tudy design. The LIFE study was an investigator-
nitiated, prospective, multinational, double-blind, double-
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September 6, 2005:770–5 Losartan-Aspirin Interaction in the LIFE Studyummy, randomized, active-controlled, parallel-group
tudy. The primary objective was to evaluate the long-term
ffects of once-daily losartan- versus atenolol-based antihy-
ertensive therapy in 55- to 80-year-old patients with
ypertension and electrocardiographically (ECG) docu-
ented LVH on the incidence of cardiovascular death,
troke, and myocardial infarction (MI). The study protocol,
esign, organization, clinical measures, end point defini-
ions, statistical considerations, baseline characteristics,
VH criteria, exclusion criteria, and main outcome have
een published (1–5,11,12). In the present analysis, patients
re stratified according to use of aspirin at baseline.
tatistical methods. All cardiovascular end points and BPs
ere analyzed using the intention-to-treat approach. The
ifference between treatment groups with respect to clinical
vents was assessed by a Cox regression model with degree
f LVH and the Framingham risk score (13) at baseline as
ovariates. This adjusted analysis with these covariates was
hosen a priori as the primary analysis to account for any
otential difference in key risk predictors at baseline. The
nteraction between treatment and aspirin was tested by
ncluding indicators for treatment group, aspirin status, and
he product of the two in the Cox regression model.
reatment effects were measured by hazard ratios (relative
isks [RRs]) and their 95% confidence intervals (CIs). The
Abbreviations and Acronyms
BP  blood pressure
CI  confidence interval
ECG  electrocardiogram
LIFE  Losartan Intervention For Endpoint reduction
in hypertension
LVH  left ventricular hypertrophy
MI  myocardial infarction
RR  relative risk
Table 1. Baseline Characteristics of Patients T
Characteristic
Demographic and clinical
Age, yrs
Women, n (%)
Blood pressure, mm Hg
Heart rate, beats/min
Body mass index, kg/m2
Cornell voltage-duration product, mm  ms
Sokolow-Lyon, mm
Framingham risk score
Current smokers, n (%)
Medical history, n (%)
Any vascular disease
Coronary heart disease
Cerebrovascular disease
Peripheral vascular disease
Atrial fibrillation
Isolated systolic hypertension*
DiabetesData are presented as mean (SD) unless otherwise indicated. *Defiisk reduction for losartan versus atenolol was calculated as
00  (1  RR). Event rates over time are presented as
aplan-Meier curves. Differences between groups in
hanges in ECG measures of LVH were analyzed with the
ilcoxon rank-sum test.
The p values for the comparison of baseline characteris-
ics for patients with and without aspirin use at baseline are
rom a chi-square test for categorical variables and ANOVA
or continuous variables. The present analyses are explor-
tory, and the p values are thus unadjusted for multiplicity.
ll tests were performed at two-sided 5% significance levels.
ESULTS
aseline demographics. At baseline, 1,970 patients
21.4% of the main study population) used aspirin: 1,004
nd 966 patients in the losartan and atenolol groups,
espectively (Table 1). Patients with aspirin use at baseline
ssigned to losartan- or atenolol-based treatment were
imilar in demographic characteristics, severity of hyperten-
ion, prevalence of coexisting cardiovascular conditions,
ramingham risk score, and ECG-LVH criteria. Compared
ith the cohort without aspirin use at baseline, the patients
sing aspirin were more likely to have a history of any
ascular disease (60% vs. 16%), stroke (25% vs. 3%), and
iabetes (17% vs. 12%) (p  0.001 for all), as shown in
able 2. Among patients with and without aspirin at
aseline, 46% and 56%, respectively, were women (p 
.001). More than 90% in the aspirin and the non-aspirin
ohorts were Caucasian.
spirin use throughout the study. The use of aspirin
hroughout the study is shown in Table 3 to illustrate the
umber of patients who remained on aspirin therapy or
witched group at different time points during the trial.
Aspirin at Baseline
Losartan
(n  1,004)
Atenolol
(n  966)
68.1 (6.8) 68.6 (6.6)
462 (46) 435 (45)
74.8/97.0 (14.1/9.1) 174.6/96.1 (14.5/9.8)
73.6 (10.8) 73.5 (11.2)
27.8 (4.8) 27.7 (4.7)
2,939 (1,170) 2,875 (1,171)
30.7 (11.0) 30.9 (10.9)
0.218 (0.093) 0.220 (0.094)
154 (15) 166 (17)
599 (60) 579 (60)
389 (39) 358 (37)
243 (24) 241 (25)
99 (10) 110 (11)
48 (5) 76 (8)
184 (18) 188 (19)
161 (16) 167 (17)aking
1nition 160/90 mm Hg.
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Losartan-Aspirin Interaction in the LIFE Study September 6, 2005:770–5tudy drug at end point or termination of follow-
p. Mean follow-up time was 4.7 years. There were 74%
nd 68% of patients who remained on study therapy
hroughout the entire follow-up time in the losartan with
spirin and atenolol with aspirin groups, respectively, com-
ared with 78% and 74% in the groups without aspirin.
lood pressure, heart rate, and LVH. In the losartan and
tenolol groups, systolic and diastolic BP levels at the last
isit were 144.0/80.2 versus 145.7/79.3 mm Hg in the
spirin cohort (p  0.060 for systolic BP and p  0.051 for
iastolic BP) and 145.0/81.9 versus 146.4/81.6 mm Hg in
he non-aspirin cohort (p  0.001 for systolic BP, p  0.33
or diastolic BP), respectively. Systolic and diastolic BPs
ere reduced by 30.8/16.8 and 28.9/16.9 mm Hg in the
osartan with aspirin and atenolol with aspirin groups,
espectively (p  0.067 for change in systolic BP and p 
.77 for diastolic BP, respectively). In patients without
spirin use, BPs were reduced by 29.9/16.6 and 28.8/16.6
m Hg in the losartan and atenolol groups, respectively (p
0.018 for change in systolic BP and p 0.95 for diastolic
P, respectively).
able 2. Baseline Characteristics of Patients With or Without A
Characteristic
With
(n 
emographic and clinical
Age, yrs 68.
Women, n (%) 89
Blood pressure, mm Hg 174.7/96.
Heart rate, beats/min 73.
Body mass index, kg/m2 27.
Cornell voltage-duration product, mm  ms 2,90
Sokolow-Lyon, mm 30.
Framingham risk score 0.24
Current smokers, n (%) 32
edical history, n (%)
Any vascular disease 1,17
Coronary heart disease 74
Cerebrovascular disease 48
Peripheral vascular disease 20
Atrial fibrillation 12
Isolated systolic hypertension* 37
Diabetes 32
ata are presented as mean (SD) unless otherwise indicated. *Definition 160/90
Dia  diastolic; NS  not significant; Sys  systolic.
Table 3. Aspirin Use Throughout the Study
Asp
No Aspirin Use at Baseline
No Yes
Day n % n
1 7,183 99.4 40
30 7,098 98.7 95
90 7,008 97.9 147
180 6,888 97.0 216
360 6,658 95.2 339
720 6,263 92.1 5381,440 5,494 86.0 898 14.0Among aspirin patients, heart rate changed from 73.6 to
1.9 beats/min, a 1.6-beat decrease in the losartan group,
nd from 73.5 to 65.6, a 7.8-beat decrease in the atenolol
roup. Among non-aspirin patients, heart rate went from
4.1 to 71.9 beats/min, a 2.1-beat decrease in the losartan
roup, and from 73.6 to 65.6, a 7.9-beat decrease in the
on-aspirin group.
At the end of the study, Cornell voltage-duration product
nd Sokolow-Lyon voltage were reduced significantly in the
osartan with aspirin cohort as compared with the atenolol
ith aspirin cohort, respectively (271 vs. 37 mm  ms,
 0.001 and 4.5 vs. 2.6 mm, p  0.001) and also in
he losartan without aspirin cohort as compared with the
tenolol without aspirin cohort (295 vs. 146 mm  ms,
 0.001 and 4.6 vs. 2.7 mm, p  0.001).
nd points in losartan- and atenolol-treated patients
aking aspirin at baseline. The primary composite end
oint (Table 4) occurred in 128 patients in the losartan
roup and in 180 patients in the atenolol group. The
djusted RR was 0.68 (95% CI 0.55 to 0.86, p  0.001).
ardiovascular mortality occurred in 56 and 76 in the
Use at Baseline
in
)
Without Aspirin
(n  7,223) p Value
) 66.6 (7.0) 0.001
4,066 (56) 0.001
3/9.5) 174.3/98.1 (14.3/8.7) Sys: NS
Dia: 0.001
0) 73.9 (11.1) NS
) 28.1 (4.8) 0.004
70) 2,807 (1,013) 0.001
9) 29.8 (10.4) 0.001
00) 0.219 (0.094) 0.001
1,179 (17) NS
1,129 (16) 0.001
722 (10) 0.001
244 (3) 0.001
311 (4) 0.001
200 (3) 0.001
954 (13) 0.001
867 (12) 0.001
Hg.
se During Trial
Aspirin Use at Baseline
No Yes
n % n %
94 4.8 1,876 95.2
83 4.2 1,874 95.8
92 4.8 1,843 95.2
106 5.5 1,807 94.5
133 7.1 1,744 92.9
152 8.4 1,647 91.6spirin
Aspir
1,970
4 (6.7
7 (46)
5 (14.
5 (11.
7 (4.7
8 (1,1
8 (10.
4 (0.1
0 (16)
8 (60)
7 (38)
4 (25)
9 (11)
4 (6)
2 (19)
8 (17)irin U
%
0.6
1.3
2.1
3.0
4.8
7.9177 10.7 1,470 89.3
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September 6, 2005:770–5 Losartan-Aspirin Interaction in the LIFE Studyosartan and atenolol groups, respectively (RR 0.73, 95% CI
.52 to 1.03, p  0.074); stroke (non-fatal and fatal)
ccurred in 61 and 94, respectively (RR 0.63, 95% CI 0.45
o 0.86, p  0.004); and MI (non-fatal and fatal) occurred
n 44 and 58, respectively (RR 0.75, 95% CI 0.51 to 1.11, p
NS). Figure 1 shows the Kaplan-Meier curves for the
rimary end point, cardiovascular mortality, stroke, and MI,
nd illustrates the interaction and time effect. The test for
nteraction (excluding other covariates) was significant for
oth the primary end point (stronger effect among patients
ith aspirin use at baseline, p  0.016 for interaction; Fig.
able 4. End Points in Losartan- and Atenolol-Treated Patients
End Point
Losartan (n  1,004)
n % Rate†
rimary composite end point‡ 128 12.7 28.3
ardiovascular mortality 56 5.6 11.8
troke 61 6.1 13.4
yocardial infarction 44 4.4 9.6
ther prespecified end points
Total mortality 106 10.6 22.4
Hospitalization for
Angina pectoris 53 5.3 11.6
Heart failure 45 4.5 9.8
Revascularization 100 10.0 22.5
New-onset diabetes§ 58 6.9 15.3
For degree of left ventricular hypertrophy and Framingham risk score at randomizatio
nfarction; patients with a first primary end point. §Among patients without diabete
CI  confidence interval.igure 1. (A) Kaplan-Meier curves for the primary end point; p  0.016 fo
C) Kaplan-Meier curves for stroke. (D) Kaplan-Meier curves for myocardial inA) and MI (losartan rate lower than atenolol rate among
atients with aspirin use at baseline, vice versa in patients
ithout aspirin use at baseline, p  0.037 for interaction;
ig. 1D). Table 5 shows the effect of losartan relative to
tenolol among patients not taking aspirin at baseline.
ISCUSSION
n this subgroup analysis of the LIFE study, there was a
reater reduction in cardiovascular death, stroke, and MI
ith losartan-based compared to atenolol-based treatment
ng Aspirin at Baseline
Atenolol (n  966) Adjusted*
Hazard Ratio
(95% CI) p Valuen % Rate†
180 18.6 42.1 0.68 (0.55–0.86) 0.001
76 7.9 16.7 0.73 (0.52–1.03) 0.074
94 9.7 21.8 0.63 (0.45–0.86) 0.004
58 6.0 13.1 0.75 (0.51–1.11) 0.16
121 12.5 26.6 0.86 (0.66–1.12) 0.26
48 5.0 10.9 1.10 (0.74–1.62) 0.64
53 5.5 12.1 0.84 (0.56–1.25) 0.39
109 11.3 25.5 0.91 (0.70–1.20) 0.51
57 7.1 15.6 0.98 (0.68–1.41) 0.91
r 1,000 patient-years of follow-up. ‡Cardiovascular mortality, stroke, and myocardial
ndomization (losartan n  843; atenolol n  799).Taki
n. †Per aspirin interaction. (B) Kaplan-Meier curves for cardiovascular death.
farction; p  0.037 for aspirin interaction.
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Losartan-Aspirin Interaction in the LIFE Study September 6, 2005:770–5n patients using aspirin than in patients not using aspirin at
aseline. Blood pressure reductions were similar with both
herapies.
The present analyses were performed on the basis of
revious reports about aspirin and angiotensin-converting en-
yme inhibitor interactions (6,7). The pharmacologic rationale
or this interaction is the common bradykinin-prostaglandin
athway (9–11,14,15). There is limited information about
ossible aspirin interactions with AT1 antagonists, except for
mall studies (14) and experimental data (15–17). However,
ossible common pathways for aspirin and AT1 (16,17) and
T2 (18) receptors have been suggested, and the AT2 recep-
ors, which are stimulated during AT1-blockade, may be
nvolved in bradykinin production (18). Thus, a pharmacologic
ationale for a possible AT1 antagonist–aspirin interaction
xists. Furthermore, because the exact signaling pathways and
unction of the other AT receptors are still in part unknown
18), interactions may be present even though the mode of
ction is unknown. Because of the common use of both aspirin
nd AT1 antagonists and the lack of data about possible
nteractions from large-scale clinical trials, the present study
as undertaken.
The present findings may be explained by a pharma-
ologic interaction, as discussed, or a selection by aspirin
se of patients more likely to respond to losartan treat-
ent. Significantly more of the patients taking aspirin at
aseline had a history of vascular disease and diabetes
ompared with the patients not taking aspirin. Because of
he relatively short duration of the study, it is not
nexpected that the differences between losartan and
tenolol are more clearly shown in the patients at highest
isk of end points. Owing to the post-hoc design of the
tudy, it cannot be concluded that losartan is equal to
tenolol in patients not taking aspirin, as suggested in
able 5. Importantly, the main findings from the LIFE
rial, a significant reduction in strokes and new-onset
iabetes, were maintained in the patients not taking
able 5. End Points in Losartan- and Atenolol-Treated Patients
End Point
Losartan (n  3,601)
n % Rate†
rimary composite end point‡ 380 10.6 22.6
ardiovascular mortality 148 4.1 8.5
troke 171 4.7 10.1
yocardial infarction 154 4.3 9.0
ther prespecified end points
Total mortality 277 7.7 15.9
Hospitalization for
Angina pectoris 107 3.0 6.3
Heart failure 108 3.0 6.3
Revascularization 161 4.5 9.5
New-onset diabetes§ 184 5.8 12.4
For degree of left ventricular hypertrophy and Framingham risk score at randomizatio
nfarction; patients with a first primary endpoint. §Among patients without diabetes
CI  confidence interval.spirin. The equal rate of new-onset diabetes in the tspirin cohort may, among other factors, be related to the
igh prevalence at baseline.
In accordance with previous publications regarding
spirin–angiotensin-converting enzyme inhibitor interac-
ion (6–8), the data have been analyzed according to aspirin
se at baseline. Although some patients started taking
spirin during the trial, Table 3 shows that there was good
eparation between the groups throughout the trial.
A first limitation may be that the present study was a
ost-hoc subgroup analysis. Thus, there was no randomiza-
ion to aspirin and aspirin use was not blinded. The patients
sing aspirin had a history of significantly more cardiovas-
ular disease than did the patients not using aspirin. Second,
predominantly white population was studied. Third, the
atients were high-risk hypertensive patients with ECG-
VH, and the outcome should be interpreted within this
ontext. Moreover, because the aspirin dosage was not
eported, we cannot assess a possible dose-dependent inter-
ction, which has been an issue in the aspirin–angiotensin-
onverting enzyme inhibitor discussion (8–10). Strengths of
he study were the large number of patients (n 1,970) and
he well-balanced distribution of the two groups with
espect to baseline characteristics, prior medical history, and
P reduction.
Losartan-based antihypertensive therapy combined
ith aspirin was more effective than an atenolol-based
reatment with aspirin in reducing the primary composite
nd point of cardiovascular morbidity and mortality and
I in a large subset of the LIFE study participants. The
ata show a statistical positive interaction between losar-
an and aspirin. Further studies are needed to clarify
hether this represents a pharmacologic interaction or a
election by aspirin use of patients more likely to respond
o losartan treatment.
cknowledgments
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